	US 12,264,186 B2
	Human hepatocyte growth factor mutant and uses thereof
Liya Nie, Beijing (CN); Songshan Xu, Beijing (CN); and Suyong Ma, Beijing (CN)
Assigned to BEIJING NORTHLAND BIOTECH CO., LTD., Beijing (CN)
Appl. No. 17/420,865
Filed by BEIJING NORTHLAND BIOTECH CO., LTD., Beijing (CN)
PCT Filed Jan. 2, 2020, PCT No. PCT/CN2020/070010 § 371(c)(1), (2) Date Jul. 6, 2021, PCT Pub. No. WO2020/143515, PCT Pub. Date Jul. 16, 2020.
Claims priority of application No. 201910010091.X (CN), filed on Jan. 7, 2019.
Prior Publication US 2022/0064242 A1, Mar. 3, 2022
Int. Cl. C07K 14/475 (2006.01); A61K 38/00 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01); A61P 25/02 (2006.01)

CPC C07K 14/4753 (2013.01) [A61P 3/10 (2018.01); A61P 9/10 (2018.01); A61P 25/02 (2018.01); A61K 38/00 (2013.01)]

10 Claims

1. A mutant of human hepatocyte growth factor (hHGF) comprising the amino acid sequence that is identical to SEQ ID NO: 1 except that the amino acid at 130^thposition of SEQ ID NO: 1 is substituted with an amino acid selected from the group consisting of arginine, histidine, and lysine.